Follow on Google News
News By Tag
News By Location
Follow on Google News
New Therapy For Lung Cancer And Related Secondary Tumors
By: Hunan Huateng Pharmaceutical Co. Ltd.
The researchers looked at the drug alectinib. Although used in standard treatments for advanced ALK-rearranged NSCLC, approximately 20 - 30% of patients treated with alectinib develop CNS metastatis, which is attributed to acquired resistance to the drug.
By treating mice first injected with tumor cells with alectinib daily for 16 weeks, the scientists obtained a mouse model displaying alectinib resistance. By biochemical analyses of the mouse brains, Yano and colleagues were able to link the resistance to the activation of a protein known as epidermal growth factor receptor (EGFR). This activation is, in turn, a result of an increase in production of amphiregulin (AREG), a protein that binds to EGFR and in doing so 'activates' it.
Based on this insight, the researchers tested the effect of administering drugs used for inhibiting the action of EGFR in combination with alectinib treatment. The experiments showed that a combination treatment of alctinib with either erlotinib or osimertinib -- two existing EGFR-inibiting drugs -- prevented the progression of CNS metastasis, controlling the condition for over 30 days.
The scientists conclude that the combined use of alectinib and EGFR-inhibitors could overcome alectinib resistance in the mouse model of leptomeningeal carcinomatosis (LMC), a particular type of CNS metastasis.
Epidermal growth factor receptor inhibitors
The drugs that Yano and colleagues tested in combination with alectinib on a mouse model were of a type known as epidermal growth factor receptor (EGFR) inhibitors, including osimertinib and erlotinib. Both are being used as medication for treating NSCLC. The former was approved in 2017 as cancer treatment by the U.S. Food and Drug Administration and the European Commission. Yano and colleagues obtained results showing that EGFR inhibitors counteract resistance to alectinib and have therefore potential in novel therapies for NSCLC and secondary cancers in the CNS.
Huateng Pharma is a professional pharmaceutical intermediates supplier with a 34000m2 industrial park and a 5000m2 R&D base. We are able to provide Anti-Cancer intermediates such as Carfilzomib intermediates, Elagolix intermediates, Palbociclib intermediates, Alectinib intermediates and so on.
Hunan Huateng Pharmaceutical Co. Ltd.
Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, P.R. China
Telephone: +86 731 89916275